Insights
Search Results
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
2.02.26
Wilson Sonsini Advises vTv on Expanded License Agreement with Newsoara
On February 2, 2026, vTv Therapeutics (vTv), a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases, announced that it has expanded its license agreement with Newsoara Biopharma providing the company with global rights to vTv's phosphodiesterase type 4 (PDE4) inhibitor, HPP737. Wilson Sonsini Goodrich & Rosati advised vTv on the transaction.
Client Highlights
1.09.26
Wilson Sonsini Advises Link Cell Therapies on Strategic Collaboration with Johnson & Johnson
On January 9, 2026, Link Cell Therapies, an oncology cell therapy company, announced a strategic collaboration with Johnson & Johnson to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., which included participation of additional strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the matter.
Client Highlights
12.17.25
Wilson Sonsini Advises Hexagon Bio on Multimillion-Dollar Joint Venture with Corteva
On December 16, 2025, Corteva, a global leader in agricultural technology, and Hexagon Bio, a biotechnology company pioneering a new way to discover nature-derived medicine, announced a multimillion-dollar joint venture (JV) to accelerate the development of new crop protection solutions inspired by nature. The JV is the first in the agriculture sector for Hexagon Bio and the first in the pharmaceutical industry for Corteva. Wilson Sonsini Goodrich & Rosati advised Hexagon Bio on the transaction.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
Client Highlights
12.16.25
Wilson Sonsini Advises Link Cell Therapies on Series A Financing
On December 15, 2025, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the transaction.
News Articles
10.01.25
LMG Life Sciences Recognizes Wilson Sonsini, Attorneys in 2025 Guide
On September 30, 2025, LMG Life Sciences announced the 2025 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result of firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012. This year, six Wilson Sonsini practices and 18 attorneys have been recognized in the guide.
Client Highlights
8.13.25
Firm Advises Kumquat on Exclusive $1.3 Billion Global License and Collaboration with Bayer
On August 12, 2025, Kumquat Biosciences Inc., a clinical-stage biotechnology company dedicated to developing life-saving cancer therapies, announced that it has entered into an exclusive global license and collaboration agreement with Bayer to develop and commercialize Kumquat’s KRAS G12D inhibitor. Under the agreement, Kumquat will initiate and complete a Phase Ia clinical study, while Bayer will lead later-stage development and commercialization activities. Wilson Sonsini Goodrich & Rosati represented Kumquat in the transaction.
Client Highlights
7.10.25
Wilson Sonsini Advises Aqtual on $31 Million Series B
On July 10, 2025, Aqtual, a Hayward, California-based precision medicine company, announced the closing of its $31 million Series B financing round. Investors in the oversubscribed round included Bold Capital, the Bold Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures, Yu Galaxy, and others. Wilson Sonsini Goodrich & Rosati advised Aqtual on the transaction.
Client Highlights
5.06.25
Wilson Sonsini Advises Stately Bio on $12 Million Seed Financing
On May 2, 2025, Stately Bio, a start-up developing cell therapies using an ML-powered live-cell imaging platform, emerged from stealth with $12 million in seed financing. The funding was led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health). The new funding will be used to scale the company’s platform technology and mature its internal pipeline of stem cell-derived therapeutics.
Client Highlights
3.26.25
Wilson Sonsini Advises Baebies on Licensing and IP Matters Related to LaCAR's Acquisition of Newborn Screening Assets
On March 12, 2025, LaCAR MDx Technologies, a company specialized in automated solutions for newborn screening, announces the strategic acquisition of newborn screening assets from Baebies, a U.S. company known for its innovative neonatal diagnostic technologies. Wilson Sonsini Goodrich & Rosati advised Baebies on licensing and intellectual property matters related to the transaction.
Client Highlights
1.07.25
Firm Advises Candid Therapeutics on Agreement with WuXi Biologics
On January 6, 2025, Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell engager developed by WuXi Biologics’ proprietary universal multispecific antibody platform, WuXiBody™. Candid plans to complete IND enabling studies to enable first-in-human studies in the first half of 2026. Wilson Sonsini Goodrich & Rosati advised Candid on technology transactions and patent matters related to the transaction.
Under the terms of the agreement, WuXi Biologics is entitled to obtain an upfront payment and development and sales milestones totaling up to $925 million, as well as royalties.
The Wilson Sonsini team advising Candid on the transaction includes:
Technology Transactions
Norm Hovijitra
Under the terms of the agreement, WuXi Biologics is entitled to obtain an upfront payment and development and sales milestones totaling up to $925 million, as well as royalties.
The Wilson Sonsini team advising Candid on the transaction includes:
Technology Transactions
Norm Hovijitra
News Articles
9.17.24
Wilson Sonsini, Attorneys Recognized in 2024 Edition of LMG Life Sciences
On September 17, 2024, LMG Life Sciences recognized several Wilson Sonsini practices and 19 of its attorneys in the 2024 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012.